## Alessia Villani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/684240/publications.pdf

Version: 2024-02-01

99 papers

1,281 citations

331670 21 h-index 434195 31 g-index

99 all docs 99 docs citations 99 times ranked 1309 citing authors

#	Article	IF	CITATIONS
1	Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatology and Therapy, 2017, 7, 1-23.	3.0	111
2	Teledermatology: a useful tool to fight COVID-19. Journal of Dermatological Treatment, 2020, 31, 325-325.	2.2	73
3	Systemic Treatment of Pediatric Psoriasis: A Review. Dermatology and Therapy, 2016, 6, 125-142.	3.0	69
4	Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. Dermatology and Therapy, 2019, 9, 209-222.	3.0	54
5	Teledermatology for acne during COVIDâ€19: high patients' satisfaction in spite of the emergency. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e662-e663.	2.4	52
6	Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clinical and Experimental Dermatology, 2016, 41, 564-566.	1.3	45
7	The Treatment of Advanced Melanoma: Therapeutic Update. International Journal of Molecular Sciences, 2022, 23, 6388.	4.1	41
8	Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma. Dermatology and Therapy, 2020, 10, 401-412.	3.0	37
9	Teledermatology and chronic skin diseases: Real life experience in a Southern Italian Dermatologic Centre. Dermatologic Therapy, 2020, 33, e13839.	1.7	34
10	Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1485-1492.	2.4	34
11	Teledermatology: A useful tool also after COVIDâ€19 era?. Journal of Cosmetic Dermatology, 2022, 21, 2309-2310.	1.6	33
12	Telemedicine and support groups could be used to improve adherence to treatment and healthâ€related quality of life in patients affected by inflammatory skin conditions during the COVIDâ€19 pandemic. Clinical and Experimental Dermatology, 2020, 45, 749-749.	1.3	31
13	Acute Localized Exanthematous Pustulosis (ALEP): Review of Literature with Report of Case Caused by Amoxicillin-Clavulanic Acid. Dermatology and Therapy, 2017, 7, 563-570.	3.0	29
14	New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma. Advances in Therapy, 2022, 39, 1164-1178.	2.9	29
15	The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy. Clinics in Dermatology, 2021, 39, 911-919.	1.6	28
16	Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt. Dermatology and Therapy, 2020, 10, 525-527.	3.0	27
17	Newâ€onset lichen planus arising after COVIDâ€19 vaccination. Dermatologic Therapy, 2022, 35, e15374.	1.7	27
18	Reply to â€~Cutaneous adverse effects of the available <scp>COVID</scp> â€19 vaccines in India: A questionnaireâ€based study' by Bawane J <i>et al</i> Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	27

#	Article	IF	Citations
19	Teledermatology for acne patients: How to reduce faceâ€toâ€face visits during COVIDâ€19 pandemic. Journal of Cosmetic Dermatology, 2020, 19, 1828-1828.	1.6	25
20	Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 758.	0.6	25
21	Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI). Dermatology and Therapy, 2019, 9, 719-724.	3.0	23
22	Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test. Dermatology and Therapy, 2019, 9, 505-510.	3.0	23
23	Reply to Woltsche N. <i>etÂal</i> . Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a singleâ€centre experience. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e145-e147.	2.4	23
24	Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opinion on Drug Safety, 2020, 19, 1585-1594.	2.4	22
25	Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature.  Dermatologic Therapy, 2020, 33, e14267.	1.7	21
26	Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opinion on Drug Safety, 2022, 21, 21-29.	2.4	21
27	Looking into a Better Future: Novel Therapies for Metastatic Melanoma. Dermatology and Therapy, 2021, 11, 751-767.	3.0	17
28	Community Knowledge About the Use, Reuse, Disinfection and Disposal of Masks and Filtering Facepiece Respirators: Results of a Study Conducted in a Dermatology Clinic at the University of Naples in Italy. Journal of Community Health, 2020, 46, 786-793.	3.8	15
29	Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment. Journal of the American Academy of Dermatology, 2020, 82, e205.	1.2	14
30	Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatologic Therapy, 2021, 34, e14857.	1.7	14
31	The reduction in the detection of melanoma during the coronavirus disease 2019 (COVID-19) pandemic in a melanoma center of South Italy. Journal of Dermatological Treatment, 2022, 33, 1778-1778.	2.2	13
32	Skin needling for the treatment of acne scarring: A comprehensive review. Journal of Cosmetic Dermatology, 2020, 19, 2174-2181.	1.6	12
33	Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series. Journal of the American Academy of Dermatology, 2021, 84, e211-e212.	1.2	12
34	Dermoscopic patterns of intradermal naevi. Australasian Journal of Dermatology, 2020, 61, 337-341.	0.7	11
35	Complete remission of an advanced basal cell carcinoma after only 3â€month treatment with sonidegib: Report of a case and drug management during <scp>COVID</scp> â€19 pandemic. Dermatologic Therapy, 2020, 33, e14200.	1.7	10
36	Expert opinion on sonidegib efficacy, safety and tolerability. Expert Opinion on Drug Safety, 2021, 20, 877-882.	2.4	10

#	Article	IF	CITATIONS
37	A Case of the Co-Existence of Subcorneal Pustular Dermatosis and Pyoderma Gangrenosum and a Review of the Literature. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1271-1274.	0.2	9
38	Letter to the editor submitted in response to "psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab― Journal of Dermatological Treatment, 2019, 30, 309-309.	2.2	9
39	Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity. Dermatology and Therapy, 2020, 10, 465-468.	3.0	8
40	Sonidegib efficacy and tolerability in advanced basal cell carcinoma: A single-center real-life experience. Journal of the American Academy of Dermatology, 2022, 86, e175.	1.2	8
41	Longâ€ŧerm results of teledermatology for acne patients during COVIDâ€19 pandemic. Journal of Cosmetic Dermatology, 2022, 21, 1356-1357.	1.6	8
42	Alopecia universalis improvement following risankizumab in a psoriasis patient. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	8
43	Psoriasis in a cohort of patients with common variable immunodeficiency. British Journal of Dermatology, 2019, 180, 935-936.	1.5	6
44	Nail changes as manifestation of systemic disease in COVIDâ€19 infection. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e474-e475.	2.4	6
45	Clinical and dermoscopic features of Spitz naevus by sex, age and anatomical site: a study of 913 Spitz naevi. British Journal of Dermatology, 2018, 179, 769-770.	1.5	5
46	Squamous Cell Carcinomas in Two Cases of Nail Lichen Planus: Is There a Real Association?. Dermatology and Therapy, 2018, 8, 491-494.	3.0	5
47	Comment on: "Second primary melanomas in a cohort of 977 melanoma patients within the first 5Âyears of monitoringâ€. Journal of the American Academy of Dermatology, 2020, 82, e107.	1.2	5
48	Cutaneous melanoma associated with naevi prevalence: A 15â€year crossâ€sectional retrospective study. Australasian Journal of Dermatology, 2020, 61, 39-42.	0.7	5
49	Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42Âmonths― Journal of the American Academy of Dermatology, 2021, 84, e299-e300.	1.2	5
50	Maskne prevalence and risk factors during the <scp>COVID</scp> â€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	5
51	The impact of <scp>COVID</scp> â€19 pandemic on nonâ€melanoma skin cancers: report of a Southern Italy referral centre. Clinical and Experimental Dermatology, 0, , .	1.3	5
52	Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on â€~A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK's first wave of the COVID-19 pandemic in a single, secondary-care dermatology department'. Clinical and Experimental Dermatology, 2022, 47, 2037-2038.	1.3	5
53	Hair Loss in Patients Treated with Vismodegib: A Single-Center Retrospective Study. Skin Appendage Disorders, 2020, 6, 280-282.	1.0	4
54	Advanced basal cell carcinoma treated with vismodegib: impact on the lives of patients and their families. Clinical and Experimental Dermatology, 2020, 45, 1044-1046.	1.3	4

#	Article	IF	CITATIONS
55	The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients. Journal of Dermatological Treatment, 2022, 33, 602-603.	2.2	4
56	Reply to: "Comparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma (laBCC) and basal cell nevus syndrome: A retrospective case series― Journal of the American Academy of Dermatology, 2020, 83, e201-e202.	1.2	4
57	Dermoscopic predictors of melanoma arising in small- and medium-sized congenital nevi. Journal of the American Academy of Dermatology, 2021, 84, 1703-1705.	1.2	4
58	Cutaneous leucocytoclastic vasculitis during secukinumab treatment. Italian Journal of Dermatology and Venereology, 2019, , .	0.2	4
59	Dermoscopy and reflectance confocal microscopy of Kaposi's sarcoma: an overview. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
60	Sonidegib treatment in patients with locally advanced basal cell carcinoma. Dermatologic Therapy, 2022, 35, e15348.	1.7	4
61	Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment. Clinical, Cosmetic and Investigational Dermatology, 2022, Volume 15, 661-673.	1.8	4
62	Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience. Dermatologic Therapy, 2019, 32, e12971.	1.7	3
63	Tinea Capitis in Campania: A 5-Year Retrospective Study in Childhood and Adolescence (2013–2018). Skin Appendage Disorders, 2019, 5, 359-361.	1.0	3
64	Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas. Dermatologic Therapy, 2020, 33, e13707.	1.7	3
65	Dermoscopic assessment of longâ€ŧerm systemic therapy with dupilumab in adult atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e701-e703.	2.4	3
66	Cutaneous Bowen's Disease: an Analysis of 182 Cases according To Age, Sex, and Anatomical Site from an Italian Center. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 696-697.	0.2	3
67	Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas. Oncologist, 2022, 27, e533-e533.	3.7	3
68	Tacrolimus ointment may improve the effectiveness of Adalimumab in patients affected by hidradenitis suppurativa: a novel promising treatment. Clinical and Experimental Dermatology, 0, , .	1.3	3
69	How reflectance confocal microscopy can help diagnose an enigmatic variant of dermatofibroma. Dermatologic Therapy, 2019, 32, e12857.	1.7	2
70	Patients with bullous disorders during <scp>COVID</scp> â€19 period: Management and adherence to treatment. Dermatologic Therapy, 2020, 33, e13697.	1.7	2
71	Phototherapy and vitamin D: the importance in COVID-19 era. Journal of Dermatological Treatment, 2022, 33, 1165-1165.	2.2	2
72	Second primary melanoma: incidence rate and risk factors. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e623-e624.	2.4	2

#	Article	IF	Citations
73	Reflectance Confocal Microscopy Identification of Subclinical Basal Cell Carcinoma after Vismodegib Treatment: Report of a Case. Dermatology and Therapy, 2021, 11, 1071-1074.	3.0	2
74	Awareness on sun protection behavior among melanoma and nonmelanoma skin cancer patients: An Italian tertiary cancer center experience. Dermatologic Therapy, 2021, 34, e14728.	1.7	2
75	Efficacy and safety of a new topical gel formulation containing retinol encapsulated in glycospheres and hydroxypinacolone retinoate, an antimicrobial peptide, salicylic acid, glycolic acid and niacinamide for the treatment of mild acne: preliminary results of a 2-month prospective study.  Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 676-679.	0.8	2
76	Vismodegib treatment in advanced basal cell carcinomas: Realâ€life experience. Dermatologic Therapy, 2022, 35, e15195.	1.7	2
77	Psoriasis awareness among general population: preliminary results of an online survey. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.2	2
78	Dermatophytid evaluated by inÂvivo reflectance confocal microscopy: a new approach?. International Journal of Dermatology, 2022, , .	1.0	2
79	Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation. Dermatologic Therapy, 2022, 35, .	1.7	2
80	It Is Not as It Seems. Skin Appendage Disorders, 2019, 5, 124-126.	1.0	1
81	Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study. Dermatologic Therapy, 2021, 34, e15036.	1.7	1
82	The remarkable increase of squamous cell carcinomas: a retrospective single-center study of 14-years study period. Italian Journal of Dermatology and Venereology, 2018, , .	0.2	1
83	Neutrophilic Dermatosis in Pregnancy: An Uncommon Course. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 2393-2394.	0.2	1
84	Psoriasis Features in Patients with Inflammatory Bowel Disease. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1001-1003.	0.2	1
85	The remarkable increase of squamous cell carcinomas: a retrospective single-center study of 14-years study period. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.2	1
86	Sonidegibâ€induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt. Dermatologic Therapy, 2022, 35, e15531.	1.7	1
87	Reflectance confocal microscopy for Kaposi's sarcoma treatment monitoring after intralesional vincristine chemotherapy. Dermatologic Therapy, 2022, , e15539.	1.7	1
88	Trends in epidemiology of melanoma in situ in a center of South″taly: Data from a melanoma reference center during the period 2004–2018. International Journal of Dermatology, 2020, 59, e444-e445.	1.0	0
89	Assessment of the adverse events related to hedgehog pathway inhibitor therapy for basal cell carcinoma: A singleâ€centre retrospective study. Australasian Journal of Dermatology, 2021, 62, e296-e297.	0.7	0
90	SMS support group in the management of acne: A useful tool to increase adherence to treatment. Dermatologic Therapy, 2021, 34, e14663.	1.7	0

#	Article	IF	Citations
91	Leiomyoma of the finger in a patient affected by cutaneous Kaposi's sarcoma. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 690-691.	0.8	0
92	Effective and tolerable treatment of advanced basal cell carcinoma with vismodegib despite other malignancies. Italian Journal of Dermatology and Venereology, $2019, \ldots$	0.2	0
93	Grover disease in a young woman: report of case. Italian Journal of Dermatology and Venereology, 2020, , .	0.2	0
94	Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation. Dermatologic Therapy, 2022, , e15332.	1.7	0
95	Effective and tolerable treatment of advanced basal cell carcinoma with vismodegib despite other malignancies. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.2	0
96	Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt. Expert Opinion on Drug Safety, 2022, , 1-2.	2.4	0
97	Teledermoscopy: a promising tool in pediatric practice. Italian Journal of Dermatology and Venereology, 2022, 157, 213-214.	0.2	0
98	Letter to the editor regarding article "Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and inâ€person visits at an academic center during the COVIDâ€19 pandemic. JÂCosmet Dermatol. 2022;21(1):36–38.― Journal of Cosmetic Dermatology, 2022, 21, 6441-6442.	1.6	0
99	Reply to: "Usage and perceptions of teledermatology in 2021: a survey of dermatologists―by Ahmad et al International Journal of Dermatology, 0, , .	1.0	O